What follow-up protocols should I implement for patients with resolved neutropenia?

For patients who have experienced and resolved neutropenia, follow-up protocols should include a thorough clinical reassessment to evaluate the patient's risk of septic complications using validated risk scoring systems by healthcare professionals competent in managing anticancer treatment complications. This reassessment should occur within 24 hours of presentation and continue daily if the patient remains at high risk. Once the risk is reassessed as low, consideration can be given to switching from intravenous to oral antibiotic therapy after 48 hours of treatment and planning for discharge, ensuring the patient understands the need to promptly return if problems develop. Empiric antibiotic therapy should be discontinued once neutropenic sepsis has responded to treatment, regardless of neutrophil count. Additionally, follow-up care should take into account the patient's social and clinical circumstances, with clear communication about signs of relapse or complications. Hospitals providing chemotherapy should have documented clinical policies specifying arrangements for ongoing care and follow-up of such patients, ensuring continuity and robustness of care including during staff absences.